Company intelligence / Profile preview

Kaysersberg Pharmaceuticals

Kaysersberg Vignoble, Grand Est, France

Ownership: Private
Employees: ~260
Development stage: Other

Overview

Kaysersberg Pharmaceuticals is an active, FDA-inspected pharmaceutical manufacturing facility specializing in sterile, single-dose, blow-fill-seal technology for liquid formulations, now operated as part of Recipharm. It is not a drug innovator or developer but serves as a contract manufacturer for regulated markets globally.

Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Recipharm (parent company, as key operational partner)Major pharma clients for sterile manufacturing (customers not publicly named)

Beyond the preview

Go deeper on Kaysersberg Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaysersberg Pharmaceuticals.

Explore the full profile